Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Literature DB >> 31125395

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Raphael J Landovitz¹, Sahar Z Zangeneh², Gordon Chau², Beatriz Grinsztejn³, Joseph J Eron⁴, Halima Dawood⁵, Manya Magnus⁶, Albert Y Liu⁷, Ravindre Panchia⁸, Mina C Hosseinipour⁹, Ryan Kofron¹, David A Margolis¹⁰, Alex Rinehart¹⁰, Adeola Adeyeye¹¹, David Burns¹¹, Marybeth McCauley¹², Myron S Cohen⁴, Judith S Currier¹.

Abstract

Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

Entities: Chemical

Keywords: CAB; HIV uninfected; cabotegravir; weight gain

Mesh：

Substances：

Year: 2020 PMID： 31125395 PMCID： PMC6938971 DOI： 10.1093/cid/ciz439

Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079

11 in total

1. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245

2. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Authors: Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min
Journal: Lancet Infect Dis Date: 2011-10-20 Impact factor: 25.071

3. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada.

Authors: John R Koethe; Cathy A Jenkins; Bryan Lau; Bryan E Shepherd; Amy C Justice; Janet P Tate; Kate Buchacz; Sonia Napravnik; Angel M Mayor; Michael A Horberg; Aaron J Blashill; Amanda Willig; C William Wester; Michael J Silverberg; John Gill; Jennifer E Thorne; Marina Klein; Joseph J Eron; Mari M Kitahata; Timothy R Sterling; Richard D Moore
Journal: AIDS Res Hum Retroviruses Date: 2015-09-09 Impact factor: 2.205

4. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

Authors: David R Bakal; Lara E Coelho; Paula M Luz; Jesse L Clark; Raquel B De Boni; Sandra W Cardoso; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn
Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790

5. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Authors: Raphael J Landovitz; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Manya Magnus; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Yinfeng Zhang; Elizabeth Tolley; Jeremy Sugarman; Ryan Kofron; Adeola Adeyeye; David Burns; Alex R Rinehart; David Margolis; William R Spreen; Myron S Cohen; Marybeth McCauley; Joseph J Eron
Journal: PLoS Med Date: 2018-11-08 Impact factor: 11.069

6. Are new antiretroviral treatments increasing the risks of clinical obesity?

Authors: Andrew Hill; Laura Waters; Anton Pozniak
Journal: J Virus Erad Date: 2019-01-01

Review 7. Long-acting injectable antiretrovirals for HIV treatment and prevention.

Authors: William R Spreen; David A Margolis; John C Pottage
Journal: Curr Opin HIV AIDS Date: 2013-11 Impact factor: 4.283

8. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.

Authors: Emanuele Di Angelantonio; Shilpa Bhupathiraju; David Wormser; Pei Gao; Stephen Kaptoge; Amy Berrington de Gonzalez; Benjamin Cairns; Rachel Huxley; Chandra Jackson; Grace Joshy; Sarah Lewington; JoAnn Manson; Neil Murphy; Alpa Patel; Jonathan Samet; Mark Woodward; Wei Zheng; Maigen Zhou; Narinder Bansal; Aurelio Barricarte; Brian Carter; James Cerhan; George Smith; Xianghua Fang; Oscar Franco; Jane Green; Jim Halsey; Janet Hildebrand; Keum Jung; Rosemary Korda; Dale McLerran; Steven Moore; Linda O'Keeffe; Ellie Paige; Anna Ramond; Gillian Reeves; Betsy Rolland; Carlotta Sacerdote; Naveed Sattar; Eleni Sofianopoulou; June Stevens; Michael Thun; Hirotsugu Ueshima; Ling Yang; Young Yun; Peter Willeit; Emily Banks; Valerie Beral; Zhengming Chen; Susan Gapstur; Marc Gunter; Patricia Hartge; Sun Jee; Tai-Hing Lam; Richard Peto; John Potter; Walter Willett; Simon Thompson; John Danesh; Frank Hu
Journal: Lancet Date: 2016-07-13 Impact factor: 79.321

9. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Authors: José M Gatell; Lambert Assoumou; Graeme Moyle; Laura Waters; Margaret Johnson; Pere Domingo; Julie Fox; Esteban Martinez; Hans-Jürgen Stellbrink; Giovanni Guaraldi; Mar Masia; Mark Gompels; Stephane De Wit; Eric Florence; Stefan Esser; François Raffi; Anton L Pozniak
Journal: AIDS Date: 2017-11-28 Impact factor: 4.177

10. Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.

Authors: D Sculier; T Doco-Lecompte; S Yerly; K J Metzner; L A Decosterd; A Calmy
Journal: HIV Med Date: 2018-06-22 Impact factor: 3.180

9 in total

1. Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?

Authors: Shahini Shah; Laura Hindley; Andrew Hill
Journal: Drugs Date: 2021-01-05 Impact factor: 9.546

Review 2. Metabolic Consequences of Antiretroviral Therapy.

Authors: Caroline E Diggins; Samuel C Russo; Janet Lo
Journal: Curr HIV/AIDS Rep Date: 2022-03-17 Impact factor: 5.071

Review 3. Promises and challenges: cabotegravir for preexposure prophylaxis.

Authors: Matthew A Spinelli; Beatriz Grinsztejn; Raphael J Landovitz
Journal: Curr Opin HIV AIDS Date: 2022-03-04 Impact factor: 4.061

4. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

Authors: Sinead Delany-Moretlwe; James P Hughes; Peter Bock; Samuel Gurrion Ouma; Portia Hunidzarira; Dishiki Kalonji; Noel Kayange; Joseph Makhema; Patricia Mandima; Carrie Mathew; Elizabeth Spooner; Juliet Mpendo; Pamela Mukwekwerere; Nyaradzo Mgodi; Patricia Nahirya Ntege; Gonasagrie Nair; Clemensia Nakabiito; Harriet Nuwagaba-Biribonwoha; Ravindre Panchia; Nishanta Singh; Bekezela Siziba; Jennifer Farrior; Scott Rose; Peter L Anderson; Susan H Eshleman; Mark A Marzinke; Craig W Hendrix; Stephanie Beigel-Orme; Sybil Hosek; Elizabeth Tolley; Nirupama Sista; Adeola Adeyeye; James F Rooney; Alex Rinehart; William R Spreen; Kimberly Smith; Brett Hanscom; Myron S Cohen; Mina C Hosseinipour
Journal: Lancet Date: 2022-04-01 Impact factor: 202.731

Review 5. Long-acting injectable cabotegravir for the prevention of HIV infection.

Authors: Meredith E Clement; Ryan Kofron; Raphael J Landovitz
Journal: Curr Opin HIV AIDS Date: 2020-01 Impact factor: 4.061

6. Factors Associated With Weight Gain in People Treated With Dolutegravir.

Authors: Lucia Taramasso; Paolo Bonfanti; Elena Ricci; Giancarlo Orofino; Nicola Squillace; Barbara Menzaghi; Giuseppe Vittorio De Socio; Giordano Madeddu; Giovanni Francesco Pellicanò; Layla Pagnucco; Benedetto Maurizio Celesia; Leonardo Calza; Federico Conti; Canio Vito Martinelli; Laura Valsecchi; Antonio Cascio; Cesare Bolla; Paolo Maggi; Francesca Vichi; Chiara Dentone; Goffredo Angioni; Antonio Mastroianni; Katia Falasca; Giovanni Cenderello; Antonio Di Biagio
Journal: Open Forum Infect Dis Date: 2020-05-26 Impact factor: 3.835